---
layout: default
title: Activated Charcoal Arnica Montana Root Lachesis Mu
parent: 僅模型預測 (L5)
nav_order: 203
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Arnica Montana Root Lachesis Mu
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Complex: Evaluation Inconclusive — No TxGNN Predictions Available

## One-Sentence Summary

This product is a multi-ingredient complex containing eight components (Activated Charcoal, Arnica Montana Root, Lachesis Muta Venom, Nerium Oleander Leaf, Peumus Boldus Leaf, Potassium Carbonate, Selenicereus Grandiflorus, and Tobacco Leaf), consistent in composition with a homeopathic/phytotherapeutic preparation. No original approved indication, no DrugBank ID, and no US market authorization were identified. The TxGNN model returned **zero predicted indications** for this query, making a repurposing evaluation impossible at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; in this case, no prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available for this candidate, so a mechanistic repurposing rationale cannot be constructed. The following observations explain why the model likely returned no output:

**Unresolvable drug identity.** The query string contains eight distinct ingredients with no unified DrugBank ID. TxGNN operates on single-entity drug nodes within its knowledge graph. A compound mixture without a registered DrugBank node cannot be anchored in the graph and therefore generates no disease predictions.

**Homeopathic/phytotherapeutic profile.** Several ingredients — Lachesis Muta Venom, Arnica Montana Root, and Selenicereus Grandiflorus Whole — are classical homeopathic materia medica entries rather than pharmacologically characterised small molecules or biologics. These substances typically lack the quantitative pharmacokinetic and target-binding data that TxGNN relies on for link prediction.

**No regulatory precedent.** The product has zero approved licenses and no Taiwan (US) market entry, removing the standard starting point for indication-extension analysis. Without an anchor indication, the "From → To" repurposing trajectory cannot be defined.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for this multi-ingredient combination.

---

## Literature Evidence

Currently no related literature available linked to this specific multi-ingredient combination as a unified drug entity.

---

## US Market Information

This product has no approved authorizations on record. No table can be generated.

---

## Safety Considerations

Please refer to individual component package inserts and relevant pharmacopoeia monographs for safety information. Specific concerns to be aware of before any further development work:

- **Nerium Oleander Leaf** contains cardiac glycosides (oleandrin, neriine); toxicity risk even at low doses.
- **Lachesis Muta Venom** is a hemotoxic/cytotoxic snake venom; homeopathic dilution status and actual concentration must be confirmed before safety assessment.
- **Tobacco Leaf** contains nicotine and minor alkaloids; combination effects with other cardiovascular-active components are unknown.
- **Potassium Carbonate** at non-homeopathic doses carries electrolyte imbalance risk.

No formal DDI data were returned. No structured warnings or contraindications were available in the Evidence Pack.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
TxGNN cannot process a multi-ingredient homeopathic complex without a single resolvable DrugBank node. There is no approved indication, no market history, and no safety dossier to support a repurposing evaluation. Proceeding without these foundations would produce unreliable outputs.

**To proceed, the following is needed:**

- **Decompose the query**: Submit each of the eight ingredients individually to TxGNN (e.g., Activated Charcoal → DB01164, Arnica Montana → separate DrugBank lookup) and aggregate predictions at the component level.
- **Confirm formulation intent**: Determine whether this is a registered homeopathic product or a novel fixed-dose combination; the regulatory pathway and evidence standard differ substantially.
- **Obtain DrugBank IDs** for each resolvable ingredient to enable knowledge-graph traversal.
- **Toxicology review for high-risk components**: Nerium Oleander and Lachesis Muta Venom require formal toxicity characterisation before any clinical development discussion.
- **Resolve data gaps DG001 and DG002**: Retrieve package insert warnings and MOA data from TFDA and DrugBank respectively before re-running the Evidence Pack pipeline.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

